CSL (Australia) Today

CSL Stock   273.72  0.58  0.21%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 9

 
High
 
Low
Low
CSL is selling for under 273.72 as of the 21st of November 2024; that is 0.21 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 273.07. CSL has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for CSL are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
CSL is entity of Australia. It is traded as Stock on AU exchange. The company has 484.21 M outstanding shares. More on CSL

Moving against CSL Stock

  0.58CBAPK Commonwealth BankPairCorr
  0.55CBAPJ Commonwealth BankPairCorr
  0.52RIO Rio TintoPairCorr
  0.51MQG Macquarie GroupPairCorr
  0.47CBA Commonwealth BankPairCorr

CSL Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. CSL's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding CSL or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, CSL's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CSL's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors)
Excise Tax ActivitiesAnimal Testing
CSL's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to CSL's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
CSL can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CSL's financial leverage. It provides some insight into what part of CSL's total assets is financed by creditors.
Liquidity
CSL cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. CSL has accumulated 12.18 B in total debt. Debt can assist CSL until it has trouble settling it off, either with new capital or with free cash flow. So, CSL's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CSL sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CSL to invest in growth at high rates of return. When we think about CSL's use of debt, we should always consider it together with cash and equity.

Total Cash From Operating Activities

4.43 Billion
CSL (CSL) is traded on Australian Securities Exchange in Australia and employs 32,698 people. CSL is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 132.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CSL's market, we take the total number of its shares issued and multiply it by CSL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. CSL operates under Biotechnology sector and is part of Health Care industry. The entity has 484.21 M outstanding shares. CSL generates positive cash flow from operations, but has no cash available
Check CSL Probability Of Bankruptcy
Ownership Allocation
CSL holds a total of 484.21 Million outstanding shares. 30% of CSL outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Therefore, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CSL Ownership Details

CSL Risk Profiles

Although CSL's alpha and beta are two of the key measurements used to evaluate CSL's performance over the market, the standard measures of volatility play an important role as well.

CSL Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in CSL without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Investing Opportunities Now

   

Investing Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

CSL Corporate Management

Elected by the shareholders, the CSL's board of directors comprises two types of representatives: CSL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSL. The board's role is to monitor CSL's management team and ensure that shareholders' interests are well served. CSL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSL's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kate PriestmanChief OfficerProfile
Paul McKenzieChief OfficerProfile
Chris CooperHead RelationsProfile
Andy SchmeltzExecutive UnitProfile
Jeffrey BallFirst OfficerProfile
BCom FCSACompany GovernanceProfile
BS BSExec CounselProfile

Additional Tools for CSL Stock Analysis

When running CSL's price analysis, check to measure CSL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CSL is operating at the current time. Most of CSL's value examination focuses on studying past and present price action to predict the probability of CSL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CSL's price. Additionally, you may evaluate how the addition of CSL to your portfolios can decrease your overall portfolio volatility.